Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma".
Journal: ACS medicinal chemistry letters
Published: September 27, 2017
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.
Journal: ACS medicinal chemistry letters
Published: April 05, 2017
Showing 1-2 of 2
Last Updated: 09/26/2026